Tandem Diabetes Care (TNDM) Deferred Taxes (2013 - 2019)

Tandem Diabetes Care (TNDM) posted Deferred Taxes of -$25000.0 for Q4 2019, up 62.85% on a QoQ basis from -$67286.0 in Q1 2014.

Tandem Diabetes Care (TNDM) Deferred Taxes (2013 - 2019) Analysis & Trends

Tandem Diabetes Care's Deferred Taxes history runs 3 years deep, the most recent figure standing at -$25000.0 for Q4 2019.

Quarterly Deferred Taxes changed N/A year-over-year to -$25000.0 in Q4 2019, while the trailing twelve-month figure through Sep 2021 was -$25000.0 (up 72.91% YoY) and the FY2020 annual result came in at -$2.1 million, down 8404.0% from the prior year.
Deferred Taxes was -$25000.0 for Q4 2019 at Tandem Diabetes Care, up from -$67286.0 in the prior quarter.
Across five years, Deferred Taxes topped out at -$25000.0 in Q4 2019 and bottomed at -$25000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	-
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-33.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-8.00 Mn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-351.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-9.40 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	7.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	51.51 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	-
10	Tandem Diabetes Care	1.16 Bn	587.46 Mn	136.79 Mn	-

Download Data